X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (19713) 19713
Newsletter (556) 556
Newspaper Article (98) 98
Book Chapter (65) 65
Dissertation (40) 40
Conference Proceeding (13) 13
Magazine Article (13) 13
Publication (13) 13
Streaming Video (3) 3
Transcript (3) 3
Book Review (2) 2
Web Resource (2) 2
Book / eBook (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
gemcitabine (17506) 17506
humans (11941) 11941
oncology (10482) 10482
chemotherapy (8657) 8657
cancer (7152) 7152
female (6942) 6942
male (6043) 6043
pancreatic cancer (6007) 6007
deoxycytidine - analogs & derivatives (5933) 5933
middle aged (5689) 5689
aged (5587) 5587
adult (4034) 4034
antineoplastic combined chemotherapy protocols - therapeutic use (4024) 4024
cisplatin (3643) 3643
survival (3453) 3453
deoxycytidine - administration & dosage (3395) 3395
treatment outcome (3304) 3304
care and treatment (2859) 2859
pancreatic neoplasms - drug therapy (2725) 2725
adenocarcinoma (2678) 2678
research (2543) 2543
therapy (2487) 2487
pancreatic neoplasms - pathology (2460) 2460
carcinoma (2248) 2248
metastasis (2217) 2217
aged, 80 and over (2181) 2181
lung neoplasms - drug therapy (2109) 2109
pharmacology & pharmacy (2077) 2077
prognosis (2052) 2052
paclitaxel (2042) 2042
trial (2038) 2038
animals (2020) 2020
cell line, tumor (1980) 1980
tumors (1885) 1885
combination (1839) 1839
carcinoma, non-small-cell lung - drug therapy (1826) 1826
deoxycytidine - therapeutic use (1794) 1794
surgery (1747) 1747
neoplasm staging (1698) 1698
antineoplastic combined chemotherapy protocols - adverse effects (1685) 1685
analysis (1680) 1680
cancer therapies (1678) 1678
apoptosis (1648) 1648
medicine & public health (1546) 1546
phase-iii trial (1527) 1527
expression (1505) 1505
survival rate (1489) 1489
antineoplastic agents - therapeutic use (1483) 1483
carboplatin (1475) 1475
disease-free survival (1460) 1460
survival analysis (1444) 1444
health aspects (1427) 1427
deoxycytidine - adverse effects (1422) 1422
retrospective studies (1377) 1377
drug therapy (1367) 1367
phase-ii trial (1365) 1365
clinical trials (1360) 1360
mice (1350) 1350
phase-ii (1310) 1310
radiotherapy (1310) 1310
docetaxel (1305) 1305
patients (1305) 1305
deoxycytidine - pharmacology (1286) 1286
cisplatin - administration & dosage (1215) 1215
gastroenterology & hepatology (1202) 1202
lung neoplasms - pathology (1161) 1161
antineoplastic agents (1124) 1124
medical prognosis (1124) 1124
adenocarcinoma - drug therapy (1120) 1120
lung cancer (1092) 1092
toxicity (1060) 1060
antimetabolites, antineoplastic - therapeutic use (1058) 1058
oncology, experimental (1056) 1056
pancreatic neoplasms - mortality (1041) 1041
antimitotic agents (1027) 1027
hematology, oncology and palliative medicine (1005) 1005
5-fluorouracil (993) 993
combined modality therapy (991) 991
drug administration schedule (967) 967
oxaliplatin (952) 952
pancreatic neoplasms - therapy (947) 947
carcinoma, non-small-cell lung - pathology (938) 938
lung cancer, non-small cell (908) 908
vinorelbine (888) 888
doxorubicin (882) 882
antineoplastic combined chemotherapy protocols - administration & dosage (880) 880
multicenter (878) 878
cell lung-cancer (873) 873
dose-response relationship, drug (858) 858
metastases (842) 842
non-small cell lung cancer (836) 836
adjuvant chemotherapy (833) 833
pancreatic neoplasms - metabolism (833) 833
adenocarcinoma - pathology (828) 828
respiratory system (798) 798
studies (788) 788
kaplan-meier estimate (777) 777
antimetabolites, antineoplastic - administration & dosage (775) 775
disease progression (775) 775
antineoplastic agents - pharmacology (769) 769
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (19781) 19781
French (261) 261
German (239) 239
Japanese (177) 177
Chinese (64) 64
Korean (62) 62
Spanish (62) 62
Italian (21) 21
Portuguese (19) 19
Polish (15) 15
Russian (12) 12
Turkish (10) 10
Czech (6) 6
Hungarian (4) 4
Norwegian (3) 3
Persian (3) 3
Slovak (3) 3
Catalan (2) 2
Romanian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Synlett, ISSN 0936-5214, 08/2014, Volume 25, Issue 13, pp. 1851 - 1854
Journal Article
International journal of pharmaceutics, ISSN 0378-5173, 01/2015, Volume 478, Issue 1, p. 308
Display Omitted 
Gemcitabine
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 08/2017, Volume 15, Issue 8, pp. 1028 - 1028
Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality multiphase imaging can help to preoperatively distinguish between... 
PHASE-III TRIAL | ADJUVANT CHEMOTHERAPY | FINE-NEEDLE-ASPIRATION | ONCOLOGY | BILIARY DRAINAGE | GEMCITABINE-BASED CHEMORADIATION | PACLITAXEL PLUS GEMCITABINE | FULL-DOSE GEMCITABINE | QUALITY-OF-LIFE | EUS-GUIDED FNA | RADIATION-THERAPY
Journal Article
Der Onkologe, ISSN 0947-8965, 05/2019, Volume 25, Issue 5, p. 466
Journal Article
Cancer, ISSN 0008-543X, 2015, Volume 121, Issue 5, pp. 673 - 680
Journal Article
Chirurg, ISSN 0009-4722, 10/2016, Volume 87, Issue 10, p. 892
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s00104-016-0282-2 
Gemcitabine
Journal Article
Gastroenterology clinics of North America, ISSN 0889-8553, 03/2012, Volume 41, Issue 1, pp. 189 - 209
Journal Article
The Surgical clinics of North America, ISSN 0039-6109, 12/2016, Volume 96, Issue 6, pp. 1391 - 1414
Journal Article
by Wang-Gillam, Andrea and Li, Chung-Pin and Bodoky, György and Dean, Andrew and Shan, Yan-Shen and Jameson, Gayle and Macarulla, Teresa and Lee, Kyung-Hun and Cunningham, David and Blanc, Jean F and Hubner, Richard A and Chiu, Chang-Fang and Schwartsmann, Gilberto and Siveke, Jens T and Braiteh, Fadi and Moyo, Victor and Belanger, Bruce and Dhindsa, Navreet and Bayever, Eliel and Von Hoff, Daniel D and Chen, Li-Tzong and Adoo, Clarence and Anderson, Thomas and Asselah, Jamil and Azambuja, Alan and Bampton, Carolyn and Barrios, Carlos Henrique and Bekaii-Saab, Tanios and Bohuslav, Melichar and Chang, David and Chen, Jen-Shi and Chen, Yeu-Chin and Choi, Hye Jin and Chung, Ik Joo and Chung, Vincent and Csoszi, Tibor and Cubillo, Antonio and DeMarco, Linda and de Wit, Maike and Dragovich, Tomislav and Edenfield, William and Fein, Luis Enrique and Franke, Fábio and Fuchs, Martin and Gonzales-Cruz, Vega and Gozza, Alberto and Fernando, Rivera Herrero and Iaffaioli, Rosario and Jakesova, Jitka and Kahan, Zsuzsanna and Karimi, Misagh and Kim, Jun Suk and Korbenfeld, Ernesto and Lang, Istvan and Lee, Fa-Chyi and Lee, Kuan-Der and Lipton, Lara and Ma, Wen Wee and Mangel, Laszlo and Mena, Raul and Palmer, Daniel and Pant, Shubham and Park, Joon Oh and Piacentini, Paolo and Pelzer, Uwe and Plazas, Javier Gallego and Prasad, Cooray and Rau, Kun-Ming and Raoul, Jean-Luc and Richards, Donald and Ross, Paul and Schlittler, Luis and Smakal, Martin and Stahalova, Vladimira and Sternberg, Cora and Seufferlein, Thomas and Tebbutt, Niall and Vinholes, Jeferson Jose and Wadlow, Raymond and Wenczl, Milkos and Wong, Mark and NAPOLI-1 Study Group and NAPOLI-1 Study Grp
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 387, Issue 10018, pp. 545 - 557
Summary Background Nanoliposomal irinotecan showed activity in a phase 2 study in patients with metastatic pancreatic ductal adenocarcinoma previously treated... 
Internal Medicine | PLUS GEMCITABINE | SURVIVAL | 5-FLUOROURACIL | MEDICINE, GENERAL & INTERNAL | ADENOCARCINOMA | 2ND-LINE CHEMOTHERAPY | OXALIPLATIN | PEP02 | DOCETAXEL | CARCINOMA | FOLFIRI | Leucovorin - administration & dosage | Humans | Middle Aged | Male | Fatigue - chemically induced | Diarrhea - chemically induced | Pancreatic Neoplasms - drug therapy | Neoplasm Metastasis | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Camptothecin - administration & dosage | Carcinoma, Pancreatic Ductal - mortality | Deoxycytidine - adverse effects | Female | Pancreatic Neoplasms - mortality | Neutropenia - chemically induced | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Pancreatic Ductal - drug therapy | Irinotecan | Vomiting - chemically induced | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Liposomes | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Pancreatic cancer | Leucovorin | Product development | Research institutes | Metastasis | Antineoplastic agents | Analysis | Antigens | Chemotherapy | Medical prognosis | Clinical trials | Drug dosages | Cancer therapies | Tumors | Adenocarcinoma | Therapy | Gemcitabine | Toxicity | Evidence-based medicine | Metastases | Nanoparticles | Randomization | Vomiting | Safety management | Toxic diseases | Neutropenia | Folinic acid | Lymphatic system | Medical treatment | Diarrhea | FDA approval | Survival | Patients | Acids | Equivalence | Interactive systems
Journal Article
Gastroenterology, ISSN 0016-5085, 2017, Volume 152, Issue 5, pp. S1269 - S1269
Journal Article
Journal Article
Journal Article
ONCOLOGY REPORTS, ISSN 1021-335X, 05/2010, Volume 23, Issue 5, pp. 1183 - 1192
Pancreatic ductal adenocarcinoma is the fourth cause of death in the Western world. Surgery remains the only treatment offering an advantage in terms of... 
targeted therapies | COMPARING GEMCITABINE | MONOCLONAL-ANTIBODY | FOLINIC ACID | ERLOTINIB PLUS GEMCITABINE | capecitabine | GROWTH-FACTOR RECEPTOR | PHASE-II TRIAL | 2ND-LINE THERAPY | ONCOLOGY | DOSE-RATE GEMCITABINE | platinum compounds | COMBINATION CHEMOTHERAPY | gemcitabine | advanced pancreatic cancer | COOPERATIVE-ONCOLOGY-GROUP | Carcinoma, Pancreatic Ductal - secondary | Pancreatic Neoplasms - metabolism | Humans | Carcinoma, Pancreatic Ductal - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Palliative Care | Vascular Endothelial Growth Factor A - metabolism | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Antimetabolites, Antineoplastic - administration & dosage | Pancreatic Neoplasms - drug therapy | Angiogenesis Inhibitors - administration & dosage | Deoxycytidine - therapeutic use | Fluorouracil - administration & dosage | Deoxycytidine - adverse effects | Chemotherapy, Adjuvant | Radiotherapy, Adjuvant | Deoxycytidine - administration & dosage | Pancreatic Neoplasms - pathology | Treatment Outcome | Clinical Trials as Topic | Evidence-Based Medicine | Carcinoma, Pancreatic Ductal - drug therapy | Protein Kinase Inhibitors - administration & dosage | Antimetabolites, Antineoplastic - therapeutic use | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Deoxycytidine - analogs & derivatives
Journal Article